Hana Biosciences is a company that is clearly moving in the right direction. The company’s lead product candidate, Marquibo, has been developed to help all cancer patients battle the deadly disease and with news released today, the concept has a great deal of backing.

The young California Company announced there is a definite agreement in place with accredited investors to sell units consisting of common stocks and warrants which will result in total cash proceeds of $12.4 million the closing of which is expected to occur prior to October 9th with Piper Jaffray and Co. serving as exclusive place agent for the transaction.

The net proceeds of this offering will be used to support the completion of the pivotal Phase 2 clinical trial of Marquibo in adult patients with Philadelphia Chromosome negative acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma in second relapse or who failed two prior lines of treatment. The

...

The rumors are back that Pfizer is negotiating to buy Wyeth, which would create a huge pharmaceutical company. br /br /blockquotePfizer, based in New York, has been negotiating with Madison, New Jersey-based Wyeth for months, one person said. A combination would create a drugmaker with annual sales of more than $70 billion, and best-selling medicines that include Pfizer’s cholesterol pill Lipitor, the world’s top-selling medicine with $12.7 billion in 2007 sales, and Wyeth’s Prevnar vaccine against pneumonia. /blockquotebr /br /Based on similar deals, the figures thrown around would put this deal around $60 billion. It is still speculation, and a few factors could push it higher. There are a few ways to look at this. To begin, I'm a Wyeth shareholder so I already am a believer in the quality of Wyeth. I think for Wyeth, a deal at $60 billion would ...